MSFrontier

Confirmed

Two or more controlled phase 3 trials met their main goal.

B-cell depletion (anti-CD20): reduce relapses and new lesions in relapsing and progressive MS

relapsing and progressive MS · B-cell depletion (anti-CD20)

Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.

Trials
10
Running now
6
Controlled phase 2/3 trials
2
People in controlled trials
1885

Deciding trials (phase 3): 2 met, 0 did not.

Other linked trials: 8

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • ASCLEPIOS Idecides the statusMet main goal

    Phase 3 · 2016 · Compared with teriflunomide · MSFT-NCT02792218

  • ASCLEPIOS IIdecides the statusMet main goal

    Phase 3 · 2016 · Compared with teriflunomide · MSFT-NCT02792231

Other linked trials: 8

These linked trials do not set the status.

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-28Trials: 8 → 10
  • 2026-10-27First listed as Confirmed

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error